Profiles of drug substances, excipients, and related methodology最新文献_第3页

Rabeprazole: A comprehensive profile. 雷贝拉唑:综合概况。

Profiles of drug substances, excipients, and related methodology Pub Date : 2021-01-01 Epub Date: 2020-08-13 DOI: 10.1016/bs.podrm.2020.07.003

Ahmed H Bakheit, Hamad M Al-Kahtani, Salem Albraiki

引用次数: 1

Series Page 系列页面

Profiles of drug substances, excipients, and related methodology Pub Date : 2021-01-01 DOI: 10.1016/s1871-5125(21)00004-2

引用次数: 0

Copyright 版权

Profiles of drug substances, excipients, and related methodology Pub Date : 2021-01-01 DOI: 10.1016/s1871-5125(21)00006-6

引用次数: 0

Bisoprolol: A comprehensive profile. 比索洛尔:一个全面的档案。

Profiles of drug substances, excipients, and related methodology Pub Date : 2021-01-01 Epub Date: 2020-09-08 DOI: 10.1016/bs.podrm.2020.07.006

Ahmed H Bakheit, Raisuddin Ali, Ali D Alshahrani, Adel S El-Azab

{"title":"Bisoprolol: A comprehensive profile.","authors":"Ahmed H Bakheit, Raisuddin Ali, Ali D Alshahrani, Adel S El-Azab","doi":"10.1016/bs.podrm.2020.07.006","DOIUrl":"https://doi.org/10.1016/bs.podrm.2020.07.006","url":null,"abstract":"The present study describes a comprehensive profile of Bisoprolol including detailed nomenclature; formulae, elemental analysis, appearance, its uses, applications, and methods for the preparation are outlined. The profile contains physicochemical properties of Bisoprolol including pKa value, solubility, X-ray powder diffraction, and methods of analysis (including compendial, electrochemical, spectroscopic, chromatographic and capillary electrophoresis). The study also covers thermal analysis such as differential scanning calorimetry and thermogravimetry of Bisoprolol. Which gives a brief idea of melting point, glass transition as well as differentiation between anhydrous and hydrated forms. In addition to these functional groups and structural confirmation of bisoprolol also presented with the help of Fourier transform infrared spectrometry and nuclear magnetic resonance spectroscopy, respectively. The mass fragmentation pattern of bisoprolol fumarate was reported using the electrospray ionization technique. Some recently reported methods for pharmacokinetic analysis of bisoprolol using high-performance liquid chromatography as well as liquid chromatography-mass spectrometry were also included in the study.","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2020.07.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38833684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Darunavir: A comprehensive profile. Darunavir:一个全面的简介。

Profiles of drug substances, excipients, and related methodology Pub Date : 2021-01-01 Epub Date: 2020-08-21 DOI: 10.1016/bs.podrm.2020.07.001

Ibrahim A Darwish, Abdulrahman A Al-Majed, Nawaf A Alsaif, Ahmed H Bakheit, Rashed N Herqash, Abdullah Alzaid

{"title":"Darunavir: A comprehensive profile.","authors":"Ibrahim A Darwish, Abdulrahman A Al-Majed, Nawaf A Alsaif, Ahmed H Bakheit, Rashed N Herqash, Abdullah Alzaid","doi":"10.1016/bs.podrm.2020.07.001","DOIUrl":"https://doi.org/10.1016/bs.podrm.2020.07.001","url":null,"abstract":"Darunavir: (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl] (isobutyl)amino}-3-hydroxy-1-phenyl-2-butanyl]carbamate is a synthetic non-peptide protease inhibitor. On June 2006, it was first approved by the Food and Drug administration (FDA) for treatment of resistant type-1 of the human immunodeficiency virus (HIV). In July 2016, the FDA expanded the approval for use of darunavir in pregnant women with HIV infection. Darunavir prevents the replication of HIV virus by inhibiting the catalytic activity of the HIV-1 protease enzyme, and selectively inhibits the cleavage of HIV encoded Gag-Pol polyproteins in virus-infected cells, which prevents the formation of mature infectious virus particles. Darunavir is unique among currently available protease inhibitors because it maintains antiretroviral activity against a variety of multidrug-resistant HIV strains. This article discusses, by a critical extensive review of the literature, the description of darunavir in terms of its names, formulae, elemental composition, appearance, and use in the treatment of HIV-infected patients. The article also discusses the methods for preparation of darunavir, its physical-chemical properties, analytical methods for its determination, pharmacological properties, and dosing information.","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2020.07.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38833681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Betaxolol: A comprehensive profile. 倍他洛尔:一个全面的概况。

Profiles of drug substances, excipients, and related methodology Pub Date : 2021-01-01 Epub Date: 2020-08-21 DOI: 10.1016/bs.podrm.2020.07.002

Majed J Al-Wadei, Ahmed H Bakheit, Alaa A-M Abdel-Aziz, Tanveer A Wani

{"title":"Betaxolol: A comprehensive profile.","authors":"Majed J Al-Wadei, Ahmed H Bakheit, Alaa A-M Abdel-Aziz, Tanveer A Wani","doi":"10.1016/bs.podrm.2020.07.002","DOIUrl":"https://doi.org/10.1016/bs.podrm.2020.07.002","url":null,"abstract":"Betaxolol is a relatively cardioselective β-adrenoceptor blocking drug, with no partial agonist (intrinsic sympathomimetic) activity and weak membrane-stabilizing (local anesthetic) activity. Betaxolol selectively and competitively binds to and blocks beta-1 (β1) adrenergic receptors in the heart, thereby decreasing cardiac contractility and rate. This leads to a reduction in cardiac output and lowers blood pressure. When applied topically in the eye, this agent reduces aqueous humor secretion and lowers the intraocular pressure (IOP). In addition, betaxolol prevents the release of renin, a hormone secreted by the kidneys that causes constriction of blood vessels. Betaxolol (S)-(-)-enantiomer shows higher pharmacological activity. This chapter provides a complete review of nomenclature, physiochemical properties, methods of preparation, identification techniques and various qualitative and quantitative analytical techniques as well as pharmacology of betaxolol. In addition, the chapter also includes review of several methods for enantiomeric separation betaxolol using chromatographic techniques.","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38832186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Preface. 前言。

Profiles of drug substances, excipients, and related methodology Pub Date : 2021-01-01 DOI: 10.1016/S1871-5125(21)00009-1

Abdulrahman A Al-Majed

引用次数: 0

Irbesartan (a comprehensive profile). 厄贝沙坦(综合概况)。

Profiles of drug substances, excipients, and related methodology Pub Date : 2021-01-01 Epub Date: 2020-08-21 DOI: 10.1016/bs.podrm.2020.07.004

Ibrahim A Darwish, Hany W Darwish, Ahmed H Bakheit, Hamad M Al-Kahtani, Zahi Alanazi

{"title":"Irbesartan (a comprehensive profile).","authors":"Ibrahim A Darwish, Hany W Darwish, Ahmed H Bakheit, Hamad M Al-Kahtani, Zahi Alanazi","doi":"10.1016/bs.podrm.2020.07.004","DOIUrl":"https://doi.org/10.1016/bs.podrm.2020.07.004","url":null,"abstract":"Irbesartan, (2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one), is a member of non-peptide angiotensin II receptor antagonists used worldwide in the treatment of hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria. Irbesartan can be used alone or in combination with other antihypertensive agents (e.g., hydrochlorothiazide). These combination products are indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapy. Irbesartan is also indicated for the treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension, an elevated serum creatinine, and proteinuria. Irbesartan exerts its action mainly via a selective blockade action on AT1 receptors and the consequent reduced pressor effect of angiotensin II. This article discusses, by a critical comprehensive review of the literature on irbesartan in terms of its description, names, formulae, elemental composition, appearance, and therapeutic uses. The article also discusses the methods for preparation of irbesartan, its physical-chemical properties, analytical methods for its determination, pharmacological-toxicological properties, and dosing information.","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2020.07.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38833682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Copyright 版权

Profiles of drug substances, excipients, and related methodology Pub Date : 2020-01-01 DOI: 10.1016/s1871-5125(20)30006-6

引用次数: 0

Profiles of Drug Substances, Excipients, and Related Methodology 原料药、赋形剂和相关方法学简介

Profiles of drug substances, excipients, and related methodology Pub Date : 2020-01-01 DOI: 10.1016/S1075-6280(02)29002-3

H. Brittain

引用次数: 414